Syndax Pharmaceuticals (NASDAQ:SNDX) Price Target Raised to $51.00 at HC Wainwright

Syndax Pharmaceuticals (NASDAQ:SNDX - Free Report) had its target price upped by HC Wainwright from $49.00 to $51.00 in a report issued on Monday morning,Benzinga reports. HC Wainwright currently has a buy rating on the stock.

SNDX has been the subject of several other research reports. StockNews.com upgraded Syndax Pharmaceuticals from a "sell" rating to a "hold" rating in a report on Friday. Barclays upped their target price on Syndax Pharmaceuticals from $32.00 to $33.00 and gave the company an "overweight" rating in a report on Thursday, August 15th. Citigroup lifted their price objective on shares of Syndax Pharmaceuticals from $30.00 to $34.00 and gave the stock a "buy" rating in a research report on Friday, August 16th. UBS Group started coverage on Syndax Pharmaceuticals in a research report on Thursday, October 24th. They set a "buy" rating and a $37.00 price target on the stock. Finally, Bank of America increased their price target on shares of Syndax Pharmaceuticals from $30.00 to $31.00 and gave the stock a "buy" rating in a report on Thursday, August 15th. Two research analysts have rated the stock with a hold rating and ten have issued a buy rating to the company's stock. According to MarketBeat.com, Syndax Pharmaceuticals presently has an average rating of "Moderate Buy" and a consensus target price of $36.18.

Syndax Pharmaceuticals Trading Up 1.8 %

Shares of Syndax Pharmaceuticals stock traded up $0.28 during trading on Monday, hitting $16.11. 4,701,100 shares of the stock were exchanged, compared to its average volume of 1,144,794. Syndax Pharmaceuticals has a 1-year low of $14.97 and a 1-year high of $25.34. The stock has a market capitalization of $1.38 billion, a price-to-earnings ratio of -4.44 and a beta of 0.92. The company has a fifty day moving average price of $18.87 and a 200-day moving average price of $20.19.

Syndax Pharmaceuticals (NASDAQ:SNDX - Get Free Report) last issued its quarterly earnings results on Tuesday, November 5th. The company reported ($0.98) EPS for the quarter, topping analysts' consensus estimates of ($1.13) by $0.15. The company had revenue of $12.50 million during the quarter, compared to the consensus estimate of $9.16 million. During the same quarter in the previous year, the business posted ($0.73) EPS. Equities research analysts forecast that Syndax Pharmaceuticals will post -3.61 EPS for the current fiscal year.

Hedge Funds Weigh In On Syndax Pharmaceuticals

Hedge funds and other institutional investors have recently made changes to their positions in the business. Mirae Asset Global Investments Co. Ltd. increased its position in Syndax Pharmaceuticals by 21.3% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,078 shares of the company's stock valued at $58,000 after purchasing an additional 541 shares during the period. Sei Investments Co. increased its position in shares of Syndax Pharmaceuticals by 2.5% during the first quarter. Sei Investments Co. now owns 40,463 shares of the company's stock valued at $963,000 after buying an additional 991 shares during the period. California State Teachers Retirement System lifted its holdings in Syndax Pharmaceuticals by 1.5% in the first quarter. California State Teachers Retirement System now owns 76,557 shares of the company's stock worth $1,822,000 after buying an additional 1,150 shares during the period. Northwestern Mutual Wealth Management Co. bought a new stake in Syndax Pharmaceuticals during the 2nd quarter valued at approximately $27,000. Finally, Ameritas Investment Partners Inc. grew its holdings in shares of Syndax Pharmaceuticals by 20.0% during the 1st quarter. Ameritas Investment Partners Inc. now owns 7,858 shares of the company's stock worth $187,000 after acquiring an additional 1,312 shares during the period.

About Syndax Pharmaceuticals

Syndax Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF).